NDC 61958-2205 – Epclusa
Velpatasvir 37.5 mg/1; Sofosbuvir 150 mg/1 · Pellet · Oral
Product NDC61958-2205
Product details
- Brand name
- Epclusa
- Generic name
- Velpatasvir and Sofosbuvir
- Labeler
- Gilead Sciences, Inc.
- Dosage form
- Pellet
- Route
- Oral
- Marketing category
- NDA · NDA214187
- Marketed since
- June 10, 2021
- Listing expires
- December 31, 2026
- Pharmacologic class
- Hepatitis C Virus NS5A Inhibitor; Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
Active ingredients
- Velpatasvir 37.5 mg/1
- Sofosbuvir 150 mg/1
Package NDC codes (1)
| Package NDC | Description | Since |
|---|---|---|
| 61958-2205-1 | 28 PACKET in 1 CARTON (61958-2205-1) / 1 PELLET in 1 PACKET | Jun 10, 2021 |
Other Epclusa products
- 61958-2201 Velpatasvir 100 mg/1; Sofosbuvir 400 mg/1 · Tablet, Film Coated · Gilead Sciences, Inc.
- 61958-2203 Velpatasvir 50 mg/1; Sofosbuvir 200 mg/1 · Tablet, Film Coated · Gilead Sciences, Inc.
- 61958-2204 Velpatasvir 50 mg/1; Sofosbuvir 200 mg/1 · Pellet · Gilead Sciences, Inc.